The Baveno Cooperation: an EASL Consortium
@BavenoCoop
Followers
2K
Following
856
Statuses
456
The official account of the Baveno Cooperation
Joined July 2021
🚨Don’t miss the Baveno VIII Pre-Symposium Webinar: Designing Clinical Studies in Advanced Chronic Liver Disease A must-attend for all liver lovers! 🗓️Wednesday, March 5, 2025 🔗Register and more info at #livertwitter
0
24
49
RT @JHepatology: 👏We extend our sincere gratitude to @ProfPaoloAngeli for his significant contributions to the @JHepatology Watch this vid…
0
7
0
❓How are surrogate outcomes validated as efficacy endpoints? 💡Learn the regulatory perspective on validation requirements and how to assess treatment response with insights from the EMA. 🔗Register: 🗓️March 5,2025 💰Free for members | €100 non-members
0
4
8
RT @rabataller: Is bariatric surgery safe and effective in patients with compensated cirrhosis ? If they have portal hypertension & varic…
0
28
0
RT @HepCommJournal: 📑 Rifaximin plus lactulose versus lactulose alone for reducing the risk of #HE recurrence‼️ Rifaximin➕lactulose was mo…
0
34
0
RT @PoseElisa: ❌💊 Simvastatin + rifaximin does not prevent ACLF development in decompensated cirrhosis ⏳10 years of work in the books 💪🏼…
0
38
0
RT @acv69cardenas: Check out our latest article. Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal h…
0
14
0
RT @NatRevGastroHep: New online! Preventing the progression of cirrhosis to decompensation and death
0
31
0
❓Do all patients respond the same way to treatment in ACLD? 💡Identify responders vs. non-responders, assess effect sizes, and explore novel approaches beyond subgroup analysis. 🔗Register: 🗓️March 5, 2025 💰Free for members | €100 non-members
0
9
33
RT @ebtapper: Congratulations to @acv69cardenas, a great editor, friend, and mentor Interesting side note: two of the three AASLD journals…
0
6
0
RT @acv69cardenas: The role of hepatologists is crucial in the care of critically ill patients with liver disease. Check out our article wi…
0
8
0
RT @DrJavierCrespo: Metabolic surgery slashes the risk of liver failure in cirrhotic MASH patients! A 15-year study shows a 72% lower risk…
0
3
0
RT @UEGJournal: Inpatients with cirrhosis are at risk of VTE: 🔴 reduced mobility ♿ 🔴 severe liver 🤕 🔴🦠 infections 🔴 acute kidney 🥊 CiThro…
0
5
0
RT @JHEP_Reports: 🟪NEW Article in press❕ "Evolving epidemiology of HCC in Spain" 🔓#OpenAccess at 👉 #LiverTwitter…
0
12
0
RT @ReibergerThomas: #LiverTwitter Will targeting immune cell responses and/or #inflammation signaling allow for reversing liver #fibrosi…
0
8
0
RT @NoureddinMD: What a day in the history of MASH! Reversal of Fibrosis in MASH cirrhotics by 24% (paired) and 17% (ITT) all sig P values.…
0
46
0
RT @dtrip2015: Delighted to share our review in @NatRevGastroHep. Preventing the progression of cirrhosis to decompensation and death. Than…
0
16
0
RT @JustSagnik: To shorten or not to shorten vasoactive agents after endoscopy....That is the question (We try to address in this IPMA!) h…
0
18
0
RT @AmerGastroAssn: 📢 New guideline: Learn how to prevent and manage hepatitis B reactivation in patients on immunosuppressive drugs. Read…
0
33
0
RT @ReibergerThomas: #LiverTwitter Aetiology-specific inflammation patterns in liver diseases. These patterns can inform #diagnostic an…
0
1
0
RT @HEP_Journal: Original Article Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalop…
0
10
0